Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavoglurant - STALICLA

Drug Profile

Mavoglurant - STALICLA

Alternative Names: AFQ-056; STP-7

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Alkynes; Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Esters; Indoles; Neuropsychotherapeutics; Nitriles; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Chorea; Cocaine-related disorders; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Obsessive-compulsive disorders; Smoking withdrawal

Most Recent Events

  • 22 Feb 2024 Stalicla in collaboration with National Institute on Drug Abuse (NIDA) plans a phase I drug-drug interaction trial (In volunteers, Treatment-naive) in Cocaine use disorder (PO) in March 2024 (NCT06273540)
  • 16 Jan 2024 STALICLA and National Institute on Drug Abuse plans a phase-III trial for Substance-related disorders in 2025
  • 18 Nov 2023 STALICLA plans a phase II trial for Alcoholism in USA (PO) (NCT06136195)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top